Leap-In Transposases and Transposons Accelerate Cell Line Development:Atum lets developers get a jump on post-transfection target protein production

摘要

Stable, high-expressing cell lines are a critical component in commercial manufacturing of therapeutic proteins and vaccines. But the time and cost of developing these lines is exacerbated by the increasing need to express complex, multisubunit proteins requiring fine control of gene expression ratios. Traditional plasmid-based random integration and viral transduction techniques have limitations that include low rate of delivery, constrained cargo size, poor stability, heterogenous populations, andpoor productivity due to gene rearrangements and silencing, all of which hamper the development of efficient production workflows.